Singapore’s Enleofen sells biotech platform rights to pharma major Boehringer

Singapore’s Enleofen sells biotech platform rights to pharma major Boehringer

09 January, 2020

Boehringer Ingelheim Enleofen Bio

Printed by Unregistered user on Fri, 12 Dec 2025 19:47:26 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Japan's Astellas Pharma buys US biotech Xyphos for $665m

Venture Capital

Chinese investors back $45m fund for biotech industry in South Australia

Read more from Singapore

Hongkong Land to launch SG private real estate fund with $6.2b in AUM

SG’s Turn Capital acquires Taiwan fashion e-tailer FRND